Chest Medicine | Page 28 of 170 | Links Medicus Content Curation & Alerts in Medicine

Opinion | Does Paxlovid help people who have been vaccinated against Covid-19? Show us the data!

19 May, 2022 | 11:07h | UTC

Does Paxlovid help people who have been vaccinated against Covid-19? Show us the data! – STAT

Review: Unexplained post-acute infection syndromes.

19 May, 2022 | 10:58h | UTC

Unexplained post-acute infection syndromes – Nature Medicine (if the link is paywalled, try this one)

Commentary on Twitter

A @NatureMedicine tour de force review of the unexplained post-acute infectious syndromes, which includes #LongCovid and many others https://t.co/5RnyY9l0eQ
by @jan_choutka @mhornig @VirusesImmunity pic.twitter.com/dhYeZYnM1U

— Eric Topol (@EricTopol) May 18, 2022

Management of drug interactions with Nirmatrelvir/Ritonavir (Paxlovid).

18 May, 2022 | 11:03h | UTC

Management of Drug Interactions With Nirmatrelvir/Ritonavir (Paxlovid®): Resource for Clinicians – Infectious Diseases Society of America

Commentary: IDSA offers guidance on managing drug interactions with nirmatrelvir/ritonavir – ACP Internist

Paxlovid’s failure as a preventative measure raises questions, but doctors still back it as a therapeutic – STAT

Yes, Relapses After Paxlovid Happen — Now What? – HIV and ID Observations

Covid-19: What is the evidence for the antiviral Paxlovid? – The BMJ

Yes, Relapses After Paxlovid Happen — Now What? – HIV and ID Observations

WHO recommends highly successful COVID-19 therapy and calls for wide geographical distribution and transparency from originator – World Health Organization

A living WHO guideline on drugs for covid-19 – The BMJ

Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 – New England Journal of Medicine

Prescribing Nirmatrelvir–Ritonavir: How to Recognize and Manage Drug–Drug Interactions – Annals of Internal Medicine

The COVID-19 Treatment Guidelines Panel’s Statement on Potential Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir (Paxlovid) and Concomitant Medications – NIH COVID-19 Treatment Guidelines Panel

Guideline Synopsis: Antithrombotic therapy for venous thromboembolism.

17 May, 2022 | 11:12h | UTC

Antithrombotic Therapy for Venous Thromboembolism – JAMA (free for a limited period)

Original Guideline: Antithrombotic Therapy for VTE Disease

Second Update of the CHEST Guideline and Expert Panel Report

Clinical update on COVID-19 for the emergency clinician: Cardiac arrest in the out-of-hospital and in-hospital settings.

17 May, 2022 | 11:05h | UTC

Clinical update on COVID-19 for the emergency clinician: Cardiac arrest in the out-of-hospital and in-hospital settings – The American Journal of Emergency Medicine

Clinical update on COVID-19 for the emergency and critical care clinician: Medical management – American Journal of Emergency Medicine

Clinical update on COVID-19 for the emergency clinician: Presentation and evaluation – The American Journal of Emergency Medicine

Cohort Study: Venous or arterial thrombosis and deaths among COVID-19 cases.

17 May, 2022 | 11:02h | UTC

Venous or arterial thrombosis and deaths among COVID-19 cases: a European network cohort study – The Lancet Infectious Diseases

Invited Commentary: Risk of arterial and venous thromboses after COVID-19 – The Lancet Infectious Diseases

News Release: COVID-19’s high blood clot risk – University of Oxford

Commentary on Twitter

Clots with Covid: Multi-national report of over 900,000 people indicates propensity of risk for arterial and venous thrombi is in men, with increasing age, and association with fatalities (4-fold in non-hospitalized) https://t.co/muGnDld4Um pic.twitter.com/6bLiHPLInm

— Eric Topol (@EricTopol) May 13, 2022

Under a Creative Commons Attribution (CC BY 4.0) license

RECOVERY Trial: Due to safety concerns, recruitment to higher dose corticosteroids closed for patients with hypoxia on no oxygen or receiving simple oxygen.

17 May, 2022 | 11:04h | UTC

Recruitment to higher dose corticosteroids closed for patients with hypoxia on no oxygen or receiving simple oxygen – University of Oxford

Cohort Study: The risk of death or unplanned readmission after discharge from a COVID-19 hospitalization.

17 May, 2022 | 11:01h | UTC

The risk of death or unplanned readmission after discharge from a COVID-19 hospitalization in Alberta and Ontario – Canadian Medical Association Journal

Commentary: Study: Readmission rate for COVID-19 is 11% – CIDRAP

RCT: Electronic cigarettes versus nicotine patches for smoking cessation in pregnancy.

17 May, 2022 | 10:59h | UTC

Electronic cigarettes versus nicotine patches for smoking cessation in pregnancy: a randomized controlled trial – Nature Medicine

News Release: E-cigarettes may be more effective than nicotine patches in helping pregnant women who smoke quit, and are just as safe – Queen Mary, University of London

Commentary: E-cigarettes ‘as safe as nicotine patches’ for pregnant smokers trying to quit – The Guardian

Commentary on Twitter (thread – click for more)

New paper in @NatureMedicine.
Results from a @NIHRresearch funded multi-centre UK trial of #ecigarettes for smoking cessation in pregnancy 🤰
Found that ECs for smoking cessation in pregnancy may be more effective than NRT.
Led by colleagues @QMUL 1/8. https://t.co/OUZxfZB4Cc

— Linda Bauld (@LindaBauld) May 16, 2022

Cohort Study: Sustainability of a clinical decision support intervention for outpatient care for emergency department patients with acute pulmonary embolism.

17 May, 2022 | 10:44h | UTC

Sustainability of a Clinical Decision Support Intervention for Outpatient Care for Emergency Department Patients With Acute Pulmonary Embolism – JAMA Network Open

Commentary on Twitter

This multicenter cohort study of ED patients with acute pulmonary embolism found the initial increase in outpatient management from a physician champion-led, EHR-embedded clinical decision support intervention was sustained 4 years later. https://t.co/UPf8pAOTry

— JAMA Network Open (@JAMANetworkOpen) May 16, 2022

M-A: Prevalence and prognostic value of preexisting sarcopenia in patients with mechanical ventilation.

17 May, 2022 | 10:27h | UTC

Prevalence and prognostic value of preexisting sarcopenia in patients with mechanical ventilation: a systematic review and meta-analysis – Critical Care

RCT: Albuterol–budesonide fixed-dose combination rescue inhaler for asthma.

16 May, 2022 | 02:33h | UTC

Albuterol–Budesonide Fixed-Dose Combination Rescue Inhaler for Asthma – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary on Twitter

The risk of severe asthma exacerbation was significantly lower with as-needed use of a fixed-dose combination of 180 μg of albuterol and 160 μg of budesonide than with albuterol alone. #ATS2022 https://t.co/MRGaUaGVwj pic.twitter.com/6BZX9Q6WxX

— NEJM (@NEJM) May 15, 2022

RCT: Effect of awake prone positioning on endotracheal intubation in patients with COVID-19 and acute respiratory failure.

16 May, 2022 | 02:37h | UTC

Effect of Awake Prone Positioning on Endotracheal Intubation in Patients With COVID-19 and Acute Respiratory Failure: A Randomized Clinical Trial – JAMA

Assessment of Awake Prone Positioning in Hospitalized Adults With COVID-19: A Nonrandomized Controlled Trial – JAMA Internal Medicine

Awake prone positioning for non-intubated patients with COVID-19-related acute hypoxaemic respiratory failure: a systematic review and meta-analysis – The Lancet Respiratory Medicine

Prone positioning of patients with moderate hypoxaemia due to covid-19: multicentre pragmatic randomised trial (COVID-PRONE) – The BMJ

RCT: Prone positioning of patients with moderate hypoxia due to COVID-19 – medRxiv

Awake prone positioning for COVID-19 acute hypoxaemic respiratory failure: a randomised, controlled, multinational, open-label meta-trial – The Lancet Respiratory Medicine

Awake prone positioning in patients with hypoxemic respiratory failure due to COVID-19: the PROFLO multicenter randomized clinical trial – Critical Care

Prone Positioning of Nonintubated Patients With Coronavirus Disease 2019—A Systematic Review and Meta-Analysis – Critical Care Medicine

Commentary on Twitter

In this trial, in patients with acute hypoxemic respiratory failure from #COVID19, prone positioning, compared with usual care without prone positioning, did not significantly reduce endotracheal intubation at 30 days. https://t.co/1RyYRtcrYj

— JAMA (@JAMA_current) May 15, 2022

Trial of a preferential Phosphodiesterase 4B Inhibitor for idiopathic pulmonary fibrosis.

16 May, 2022 | 02:32h | UTC

Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary on Twitter

https://twitter.com/NEJM/status/1525878684380430343

RCT: Comparison of 8 versus 15 days of antibiotic therapy for Pseudomonas aeruginosa ventilator-associated pneumonia in adults.

16 May, 2022 | 02:30h | UTC

Comparison of 8 versus 15 days of antibiotic therapy for Pseudomonas aeruginosa ventilator-associated pneumonia in adults: a randomized, controlled, open-label trial – Intensive Care Medicine (free article here)

Commentary on Twitter

🧫 8 vs 15 days ABT for Pseudomonas aeruginosa VAP in adults, iDIAPASON RCT: no differences in composite or separate outcomes (90-day mortality/VAP recurrence) between short & long duration treatment.
📢 @yourICM ground-breaking release #LIVES40 #FOAMcc
🖇 https://t.co/LfoUWxCkkl pic.twitter.com/XaWkQ5R6wT

— Intensive Care Medicine (@yourICM) May 13, 2022

International evidence-based recommendations for point-of-care lung ultrasound.

16 May, 2022 | 02:20h | UTC

International evidence-based recommendations for point-of-care lung ultrasound – Intensive Care Medicine (if the link is paywalled, try this one)

Molecular diagnostics in severe pneumonia: a new dawn or false promise?

16 May, 2022 | 01:43h | UTC

Molecular diagnostics in severe pneumonia: a new dawn or false promise? – Intensive Care Medicine

Commentary on Twitter

Pneumonia? no gold standard diagnosis available, likely resulting in overtreatment. Molecular diagnostics more widely available even if interpretation/use complex, requiring to take into account data/characteristics when making decisions based on these.
📎 https://t.co/mae0vxBfkF pic.twitter.com/bbkxGLEumN

— Intensive Care Medicine (@yourICM) May 14, 2022

Review of thoracic imaging manifestations of COVID-19 and other pathologic Coronaviruses.

13 May, 2022 | 11:36h | UTC

Review of Thoracic Imaging Manifestations of COVID-19 and Other Pathologic Coronaviruses – Radiology Clinics of North America

New versions of Omicron are masters of immune evasion.

13 May, 2022 | 11:37h | UTC

New versions of Omicron are masters of immune evasion – Science

Commentary on Twitter

"Based on its immunological profile, it [Omicron & its subvariants] should be called SARS-3"https://t.co/zxV3T2SKIB @gretchenvogel @NewsfromScience
w/ @K_G_Andersen @Tuliodna @linfa_wang pic.twitter.com/ToKDqNGH74

— Eric Topol (@EricTopol) May 12, 2022

IDSA updates guidelines on the treatment and management of patients with COVID-19.

13 May, 2022 | 11:35h | UTC

IDSA Guidelines on the Treatment and Management of Patients with COVID-19 – Infectious Diseases Society of America

Cohort Study: Health outcomes in people 2 years after surviving hospitalization with COVID-19.

13 May, 2022 | 11:32h | UTC

Health outcomes in people 2 years after surviving hospitalisation with COVID-19: a longitudinal cohort study – The Lancet Respiratory Medicine

News Release: Two years after infection, half of people hospitalized with COVID-19 have at least one symptom, follow-up study suggests – Lancet

[Preprint] Long Covid: A systematic review and meta-analysis of 120,970 patients.

13 May, 2022 | 11:30h | UTC

Long Covid: A Systematic Review and Meta-Analysis of 120,970 Patients – Preprints with The Lancet

Commentary on Twitter

A systematic #LongCovid review of nearly 200 studies and over 120,000 participants, reinforces the high frequency of symptoms > 6 months, not linked to severity of acute illness, and potential for marked disabilityhttps://t.co/9NYQT1P79G pic.twitter.com/WFzBqghbGI

— Eric Topol (@EricTopol) May 6, 2022